Sarepta Therapeutics Inc (SRPT)
123.07
-0.22
(-0.18%)
USD |
NASDAQ |
Nov 04, 16:00
122.78
-0.29
(-0.24%)
Pre-Market: 09:06
Sarepta Therapeutics Cash from Investing (Quarterly): -98.53M for June 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -98.53M |
| March 31, 2024 | 218.80M |
| December 31, 2023 | -64.36M |
| September 30, 2023 | -210.57M |
| June 30, 2023 | 96.63M |
| March 31, 2023 | 12.49M |
| December 31, 2022 | 9.796M |
| September 30, 2022 | 19.12M |
| June 30, 2022 | -289.99M |
| March 31, 2022 | -785.81M |
| December 31, 2021 | -2.577M |
| September 30, 2021 | 20.26M |
| June 30, 2021 | 321.06M |
| March 31, 2021 | 156.67M |
| December 31, 2020 | -123.89M |
| September 30, 2020 | 54.08M |
| June 30, 2020 | -34.22M |
| March 31, 2020 | -17.68M |
| December 31, 2019 | 17.08M |
| September 30, 2019 | -17.96M |
| June 30, 2019 | 152.37M |
| March 31, 2019 | 135.23M |
| December 31, 2018 | -237.74M |
| September 30, 2018 | -63.40M |
| June 30, 2018 | -55.09M |
| Date | Value |
|---|---|
| March 31, 2018 | -14.26M |
| December 31, 2017 | -493.70M |
| September 30, 2017 | 124.95M |
| June 30, 2017 | -20.05M |
| March 31, 2017 | 209.98M |
| December 31, 2016 | -198.77M |
| September 30, 2016 | 10.22M |
| June 30, 2016 | 78.94M |
| March 31, 2016 | 19.42M |
| December 31, 2015 | -69.82M |
| September 30, 2015 | 31.02M |
| June 30, 2015 | 3.383M |
| March 31, 2015 | 43.83M |
| December 31, 2014 | 46.68M |
| September 30, 2014 | -20.54M |
| June 30, 2014 | -2.877M |
| March 31, 2014 | -182.29M |
| December 31, 2013 | -0.822M |
| September 30, 2013 | -1.677M |
| June 30, 2013 | -1.453M |
| March 31, 2013 | -7.72M |
| December 31, 2012 | -0.423M |
| September 30, 2012 | -0.081M |
| June 30, 2012 | -0.379M |
| March 31, 2012 | -0.262M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-785.81M
Minimum
Mar 2022
321.06M
Maximum
Jun 2021
-36.93M
Average
9.796M
Median
Dec 2022
Cash from Investing (Quarterly) Benchmarks
| Regenxbio Inc | -0.268M |
| Catalyst Pharmaceuticals Inc | -0.01M |
| Vertex Pharmaceuticals Inc | -463.70M |
| Entrada Therapeutics Inc | -24.38M |
| Edgewise Therapeutics Inc | 37.37M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 14.94M |
| Cash from Financing (Quarterly) | 39.92M |
| Free Cash Flow | -527.92M |
| Free Cash Flow Per Share (Quarterly) | -0.1435 |
| Free Cash Flow to Equity (Quarterly) | -1.294M |
| Free Cash Flow to Firm (Quarterly) | -14.22M |
| Free Cash Flow Yield | -4.39% |